Hetero Drugs Ltd, part of Rs 500 crore Hetero group that focusses on anti-AIDS drugs, has received a $10 million order from the government of Brazil for supply of two latest anti-AIDS drugs -- Lopinavir and Ritonavir. The order will be executed over the next one year.
With the supply of these two drugs, which are patented by Abbott Laboratories, the company hopes to increase its exports to Latin American countries.
Hetero is one of the major suppliers of anti-AIDS drugs for Latin American markets. "Of the Rs 189 crore of our exports to Latin America during the current year, the share of anti-AIDS drugs was Rs 120 crore," M Srinivas Reddy, director of Hetero, said.
"We were the first company from India to enter the anti-AIDS drugs export market. Before our entry in 1997, Brazil had an annual budget of $600 million to offer treatment to 1 lakh patients. Now, the Brazilian government is able to offer treatment for 7 lakh patients with a budget of $300 million," Reddy added.
A closely-held company, Hetero was promoted by B Pardha Saradhi Reddy in 1993. The company produces 13 anti-AIDS drugs out of the 14 drugs available worldwide. The company occupies second position, next to Cipla, in the Rs 25 crore Indian anti-AIDS drugs market.
The company also produces bulk drugs over a wide range of therapeutic categories with five products approved by US FDA. It has also established a research foundation with an investment of Rs 25 crore for the development of non-infringing, cost-effective processes and custom synthesis contract research.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
